| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Acetyl hexapeptide-1 acetate is a cosmetic peptide that mimics the body's own peptides. It is designed to target the underlying mechanisms of skin aging. While its precise molecular target is not detailed, it is part of a class of peptides that function as signaling molecules, potentially interacting with cell surface receptors on fibroblasts or keratinocytes to stimulate extracellular matrix production (e.g., collagen, elastin). It is sometimes classified as a neurotransmitter-affecting peptide.
|
|---|---|
| ln Vitro |
The specific in vitro activity is not detailed in the search results. However, as a peptide with anti-wrinkle benefits, its activity is likely measured by its ability to stimulate collagen synthesis in dermal fibroblasts. In vitro assays typically measure the production of procollagen type I (PIP) and elastin in cultured human fibroblasts via ELISA. A positive effect is a statistically significant increase in these markers compared to a vehicle control.
|
| ln Vivo |
Specific in vivo activity data was not provided. As a cosmetic ingredient, its activity is generally studied in human clinical trials, not animal models. These trials involve twice-daily application of a cream containing the peptide to the face (e.g., crow's feet area) for 4-8 weeks. Wrinkle depth, volume, and roughness are measured using optical profilometry or 3D imaging. A statistically significant reduction in wrinkle parameters compared to a placebo cream indicates in vivo efficacy.
|
| Enzyme Assay |
Not applicable. Acetyl hexapeptide-1 is a peptide and does not have an enzymatic or receptor target in a cell-free binding context. Its activity is typically measured in cell-based assays or clinical studies. As a research cosmetic ingredient, its purity (>98%) is confirmed by HPLC, and its identity by mass spectrometry.
|
| Cell Assay |
The in vitro activity can be assessed using human dermal fibroblasts. Procedure: Human primary dermal fibroblasts are seeded in 24-well plates (1x10^5 cells/well) and grown to 80% confluency. The culture medium is replaced with serum-free medium containing varying concentrations (e.g., 1, 10, 50, 100 microM) of Acetyl hexapeptide-1 acetate. After 48 hours of incubation, the culture supernatant is collected. The levels of type I collagen and elastin are measured using human-specific ELISA kits. Cell viability is assessed using MTT to ensure non-toxicity. The EC50 for collagen production can be calculated.
|
| Animal Protocol |
In vivo activity is typically assessed in human clinical trials, not in animals, as the compound is a cosmetic ingredient. A typical clinical trial protocol involves 30 healthy female volunteers aged 40-65 with moderate periorbital wrinkles. The volunteers apply a cream formulation containing 0.005% Acetyl hexapeptide-1 acetate twice daily for 56 days. Wrinkle parameters are measured using a 3D fringe projection system on days 0, 28, and 56. The primary endpoints are changes in maximum wrinkle depth (Rmax), average roughness (Ra), and total wrinkle area. A safety evaluation is performed by a dermatologist.
|
| ADME/Pharmacokinetics |
Specific PK data for Acetyl hexapeptide-1 acetate is not applicable. As a peptide, it is expected to have poor oral bioavailability. For its intended use as a topical cosmetic ingredient, it is designed to remain on the surface of the skin or penetrate the stratum corneum to exert its effects locally. It is not intended to reach systemic circulation. The molecule is too large (MW 930) to readily cross the intact skin barrier and enter the bloodstream.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for Acetyl hexapeptide-1 acetate is not provided. As a cosmetic ingredient, it has been used in numerous safety assessments and is generally recognized as safe for topical use at the recommended concentrations. It is non-irritating and non-sensitizing. Standard safety data sheets for research-grade compounds indicate it should be handled with appropriate safety precautions, but no significant hazard has been identified for this peptide.
|
| References | |
| Additional Infomation |
Acetyl hexapeptide-1 acetate is a member of the "peptide" class of anti-aging ingredients that have become popular in cosmetics. It is often referred to as a "botox-like" peptide due to its potential to inhibit neurotransmitter release, thereby reducing muscle-induced expression lines. It is one of many synthetic peptides used in skincare formulations to target signs of aging by promoting extracellular matrix production and improving skin barrier function. This product is a research-grade standard for the development and quality control of cosmetic formulations and is not an approved drug.
|
| Molecular Formula |
C45H63N13O9
|
|---|---|
| Molecular Weight |
930.06
|
| CAS # |
2828433-36-7
|
| Appearance |
White to off-white solid powder
|
| SMILES |
NC(NCCC[C@H](NC([C@H](NC([C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCC)NC(C)=O)CC1N=CNC=1)=O)CC1=CC=CC=C1)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(N)=O)=N.OC(=O)C
|
| Synonyms |
Melitane acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~39 mg/mL (~41.93 mM; with heating and sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0752 mL | 5.3760 mL | 10.7520 mL | |
| 5 mM | 0.2150 mL | 1.0752 mL | 2.1504 mL | |
| 10 mM | 0.1075 mL | 0.5376 mL | 1.0752 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
